Everolimus + Tacrolimus + Mycophenolic acid
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Kidney; Complications, Allograft
Conditions
Kidney; Complications, Allograft
Trial Timeline
Mar 1, 2013 → Dec 1, 2015
NCT ID
NCT02036554About Everolimus + Tacrolimus + Mycophenolic acid
Everolimus + Tacrolimus + Mycophenolic acid is a approved stage product being developed by Novartis for Kidney; Complications, Allograft. The current trial status is unknown. This product is registered under clinical trial identifier NCT02036554. Target conditions include Kidney; Complications, Allograft.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02036554 | Approved | UNKNOWN |
Competing Products
20 competing products in Kidney; Complications, Allograft